Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOXO-305 vs bendamustine + rituximab in relapsed/refractory CLL/SLL after covalent BTK inhibitors
CTR20212373Phase 3Completed
- Sponsor
- Loxo Oncology
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pirtobrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Loxo Oncology. Started Sep 2021; status: completed.
02
Drugs
pirtobrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on CTR20212373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212373.